BioSpace News Archive

Regulatory News: Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France.

Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation.

Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration has granted Orphan Drug Designation to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

CellOrigin Biotech Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages for cancer immnotherapy.

AstraZeneca’s IMFINZI® has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy.

Apexigen, Inc. a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, announced the presentation of new data from a Phase 2 clinical trial evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction cancers.

Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Clarity Pharmaceuticals is pleased to announce that the US-based diagnostic 64Cu SAR-Bombesin trial for patients with PSMA-negative prostate cancer is open for recruitment.

Bristol Myers Squibb announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology Congress 2022 from September 9-13 in Paris, France.

Clarus Therapeutics Holdings, Inc. announced that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.